CUBE TECH FAIR 2017: Experience the 4th Industrial Revolution

10 - 12 May 2017, Berlin, Germany.
The new annual CUBE TECH FAIR will showcase the pioneering and disruptive innovations and technologies that the top team of connectors and partners have hand picked globally. Interact with B2B startups, corporate executives, institutions and thought leaders that have been enabled by CUBE throughout the year.

CUBE TECH FAIR gives you fast and direct access to the most relevant B2B startup for your business:

  • Get premier access to B2B startups and more than 500 CEOs from B2B startups of all sizes and industries.
  • Experience and access innovations and disruptive technologies as well as outstanding projects.
  • Get connected to expertise and knowledge across different industries from digital health to manufacturing.

Hello Startups! Ready to boost your business?
Want to show the most relevant executives what you've got and engage in partnerships that help you scale up fast? Be part of the CUBE TECH FAIR 2017 in Berlin:

  • Meet 2,000+ business leaders, entrepreneurs, executives, investors, technology influencers, startup ecosystem leaders, institutions, and other brilliant minds.
  • Get premiere access to the industry and to their distribution channels. Show them how you can revolutionize the industry 4.0.
  • Opportunity for scaling up fast and short time to market through partnership with corporates.
  • Get globally connected to corporate expertise and knowledge across different industries from digital health to manufacturing.

Brilliant minds get their ticket now.

World Pharma News readers can benefit from an exclusive discount - get 30% off the ticket price using our unique promo code worldpharmanewsCUBE17 when you register online here.

Hint: The faster you buy your ticket, the cheaper it is.

About CUBE
CUBE is a Berlin-based global innovation ecosystem that aims to promote, create and foster partnerships between industry players and startups in life sciences & digital health, machinery & manufacturing as well as infrastructure & connectivity. Being part of the CUBE ecosystem allows all participants to collaborate on innovative products and ideas in response to concrete industry needs.

The annual CUBE Tech Fair, our flagship event, will take place for the first time in May 2017. For further information, please visit http://tech-fair.cube-global.com.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]